Key result
Exenatide undergoes evaluation versus standard care for early neurological improvement in acute ischemic stroke.
RCT (n=528)
Open-label with blinded end-point
Randomized
Yes
Answers are grounded in this paper and cite their sources.
Rationale Post-stroke hyperglycemia occurs in up to 50% of patients presenting with acute ischemic stroke. It reduces the efficacy of thrombolysis, increases infarct size, and worsens clinical outcomes. Insulin-based therapies have generally not been beneficial in treating post-stroke hyperglycemia as they are difficult to implement, may cause hypoglycaemia, possibly increase mortality and worsen clinical outcomes. Exenatide may be a safer, simpler, and more effective alternative to insulin in acute ischemic stroke. Design TEXAIS is a three year, Phase 2, multi-center, prospective, randomized, open label, blinded end-point trial comparing exenatide to standard of care. It aims to recruit 528 patients with a primary end point of major neurological improvement at 7 days defined as a ≥8-point improvement in NIHSS score, or NIHSS 0-1. Secondary outcomes of hyper- and hypoglycaemia at 5 days and NIHSS and mRS at 90 days will be measured. The treatment arm will receive exenatide 5 µg subcutaneously twice daily. The control arm will receive standard stroke unit care. Continuous glucose monitors will track the dynamic variability of glucose. Conclusion TEXAIS aims to show that exenatide is safe and effective in the treatment of post-stroke hyperglycemia. It has been designed to be highly generalizable with an ability to enroll a large percentage of patients with acute ischemic stroke, regardless of admission blood glucose level, diabetes status, or stroke severity, with very low risk of hypoglycemia. Trial registration: ClinicalTrials.gov/ANZCTR NTA1127.
No takes yet. Share an insight, caveat, or question.
Muller et al. (2018) conducted an RCT in Acute ischemic stroke with post-stroke hyperglycemia (n=528). Exenatide vs. Standard stroke unit care was evaluated on Major neurological improvement at 7 days (defined as a ≥8-point improvement in NIHSS score, or NIHSS 0-1). Exenatide twice daily is being evaluated against standard care in 528 acute ischemic stroke patients for major neurological improvement at 7 days (≥8-point NIHSS improvement or NIHSS 0-1).
Synapse has enriched 10 related papers. Consider them for comparative context: